Pharsight

Ultravate generic

Ultravate is an effective corticosteroid-responsive dermatoses treatment drug owned by Sun Pharm Industries. The drug, which contains the active ingredient halobetasol propionate, was first authorized for market use on November 6, 2015.

When will Ultravate generic be available?

The generic version of Ultravate is not yet available. The last patent, which plays a vital role in determining the generic release date, will expire on June 19, 2033. Therefore, we can expect the Ultravate generic version to hit the market after this date.

Ultravate uses

Ultravate, available in lotion and topical forms, uses halobetasol propionate and is effective in treating a range of conditions. In particular, it is used for the treatment of corticosteroid-responsive dermatoses, including psoriasis.

Ultravate patent expiration

Ultravate has a total of one drug patent, none of which have expired yet. The last patent, titled 'Topical steroid composition and method', will expire on June 19, 2033. After this date, the Ultravate generic could potentially become available. Below are the details of the patent:

Ultravate dosage

Want to ask something?